3.51
price up icon3.54%   0.12
 
loading
Genelux Corp stock is traded at $3.51, with a volume of 66,738. It is up +3.54% in the last 24 hours and up +24.03% over the past month. Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
See More
Previous Close:
$3.39
Open:
$3.32
24h Volume:
66,738
Relative Volume:
0.46
Market Cap:
$132.54M
Revenue:
-
Net Income/Loss:
$-27.66M
P/E Ratio:
-3.6947
EPS:
-0.95
Net Cash Flow:
$-24.36M
1W Performance:
+5.09%
1M Performance:
+24.03%
6M Performance:
-11.14%
1Y Performance:
+79.08%
1-Day Range:
Value
$3.32
$3.56
1-Week Range:
Value
$3.30
$3.70
52-Week Range:
Value
$1.60
$5.885

Genelux Corp Stock (GNLX) Company Profile

Name
Name
Genelux Corp
Name
Phone
805-267-9889
Name
Address
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Name
Employee
24
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
GNLX's Discussions on Twitter

Compare GNLX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
GNLX
Genelux Corp
3.51 128.01M 0 -27.66M -24.36M -0.95
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
462.13 117.32B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.87 58.89B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
401.80 51.14B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
673.80 41.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.01 32.59B 3.81B -644.79M -669.77M -6.24

Genelux Corp Stock (GNLX) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-29-24 Initiated Guggenheim Buy
Aug-28-24 Initiated ROTH MKM Buy
Nov-27-23 Initiated H.C. Wainwright Buy
Sep-12-23 Initiated Maxim Group Buy
Feb-15-23 Initiated The Benchmark Company Speculative Buy

Genelux Corp Stock (GNLX) Latest News

pulisher
12:10 PM

What are the latest earnings results for Genelux CorporationMarket Forecast Signals For Fast Growth - jammulinksnews.com

12:10 PM
pulisher
Aug 01, 2025

How Genelux Corporation stock performs during market volatilityCapital Growth Summary Over Five Years - Newser

Aug 01, 2025
pulisher
Aug 01, 2025

How to use a screener to detect Genelux Corporation breakoutsDividend Strategy Summary With 10-Year Outlook - Newser

Aug 01, 2025
pulisher
Jul 30, 2025

Genelux Corporation Added to High Probability Setup ListHigh Conviction Intraday Stock Signals Detected - metal.it

Jul 30, 2025
pulisher
Jul 29, 2025

How Efficient Is Genelux Corporation at Controlling Operating CostsRisk Aware Swing Trade Analysis Insights - Newser

Jul 29, 2025
pulisher
Jul 29, 2025

Can trapped investors hope for a rebound in Genelux CorporationValue Holding Return Summary With Outlook - Newser

Jul 29, 2025
pulisher
Jul 28, 2025

Does Genelux Corporation stock perform well during market downturnsAchieve unparalleled market performance - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Using AI based signals to follow Genelux CorporationEarnings Report Summary with Market Impact - Newser

Jul 28, 2025
pulisher
Jul 27, 2025

Is it the right time to buy Genelux Corporation stockGet alerts on the hottest market movers - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 24, 2025

What drives Genelux Corporation stock priceBreakthrough investment results - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

Genelux Corporation Stock Analysis and ForecastTriple returns potential - Autocar Professional

Jul 24, 2025
pulisher
Jul 23, 2025

Genelux stock maintains Buy rating at H.C. Wainwright amid sector news - Investing.com India

Jul 23, 2025
pulisher
Jul 23, 2025

Genelux stock maintains Buy rating at H.C. Wainwright amid sector news By Investing.com - Investing.com South Africa

Jul 23, 2025
pulisher
Jul 23, 2025

Promising Prospects for Genelux Corp.’s Olvi-Vec: A Buy Rating Based on Strong Clinical Trial Design and Efficacy - TipRanks

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Genelux Corporation stockOutstanding risk-reward balance - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 21, 2025

Lucid Capital Initiates Coverage on Genelux with a Buy Rating, Setting a Price Target of $10. - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

Lucid Capital Initiates Coverage of Genelux with Buy Rating and $10 Price Target - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

Genelux: LUCID CAPITAL MARKETS Initiates Buy Coverage, PT $10 - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

Lucid Capital Markets initiates Genelux stock with Buy rating, $10 target By Investing.com - Investing.com South Africa

Jul 21, 2025
pulisher
Jul 21, 2025

Lucid Capital Markets initiates Genelux stock with Buy rating, $10 target - Investing.com Nigeria

Jul 21, 2025
pulisher
Jul 21, 2025

Genelux initiated with a Buy at Lucid Capital - TipRanks

Jul 21, 2025
pulisher
Jul 20, 2025

Is Genelux Corporation a good long term investmentExceptional portfolio growth - Autocar Professional

Jul 20, 2025
pulisher
Jul 19, 2025

Genelux Corp: A Promising Investment in the Oncolytic Virus Space with Key Clinical Milestones Ahead - TipRanks

Jul 19, 2025
pulisher
Jul 19, 2025

What risks could impact Genelux Corporation stock performanceExpert Trading Flow - Newser

Jul 19, 2025
pulisher
Jul 18, 2025

Genelux Corporation (NASDAQ:GNLX) Position Trimmed by Stratos Wealth Partners LTD. - Defense World

Jul 18, 2025
pulisher
Jul 15, 2025

Why Genelux Corporation stock attracts strong analyst attentionProven Win Setups - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Genelux Corporation stock price move sharplyFree VIP Investment Strategies - Newser

Jul 15, 2025
pulisher
Jul 12, 2025

Genelux (NASDAQ:GNLX) Raised to “Hold” at Wall Street Zen - Defense World

Jul 12, 2025
pulisher
Jul 08, 2025

Amgen Alum Takes Legal Reins of Biotech Firm Developing Cancer Treatment - Law.com

Jul 08, 2025
pulisher
Jul 07, 2025

Genelux Appoints Groen as General Counsel From Rani Therapeutics - Bloomberg Law News

Jul 07, 2025
pulisher
Jul 07, 2025

Biopharma Co. Genelux Hires Life Sciences Veteran As GC - Law360

Jul 07, 2025
pulisher
Jul 07, 2025

Genelux appoints Eric Groen as general counsel, corporate secretary, CCO - TipRanks

Jul 07, 2025
pulisher
Jul 07, 2025

Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development - MarketScreener

Jul 07, 2025
pulisher
Jul 07, 2025

Former Amgen $10B Deal Architect Joins Genelux Leadership to Drive Strategic Growth - Stock Titan

Jul 07, 2025
pulisher
Jul 02, 2025

Genelux Corporation (NASDAQ:GNLX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World

Jul 02, 2025
pulisher
Jun 16, 2025

June 2025's Promising Penny Stocks For Savvy Investors - simplywall.st

Jun 16, 2025
pulisher
Jun 14, 2025

Two Sigma Investments LP Sells 18,446 Shares of Genelux Co. (NASDAQ:GNLX) - Defense World

Jun 14, 2025
pulisher
Jun 12, 2025

Citadel Advisors LLC Lowers Position in Genelux Co. (NASDAQ:GNLX) - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Millennium Management LLC Cuts Stake in Genelux Co. (NASDAQ:GNLX) - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Genelux Co. (NASDAQ:GNLX) Shares Sold by Squarepoint Ops LLC - Defense World

Jun 11, 2025
pulisher
Jun 08, 2025

Wall Street Zen Downgrades Genelux (NASDAQ:GNLX) to Sell - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

Genelux Co. (NASDAQ:GNLX) Given Average Recommendation of “Buy” by Brokerages - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

Genelux (NASDAQ:GNLX) Trading Up 3.3% – Time to Buy? - Defense World

Jun 06, 2025
pulisher
Jun 02, 2025

Genelux Corporation (GNLX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Jun 02, 2025

Genelux Corp Stock (GNLX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$75.59
price up icon 0.93%
$37.11
price up icon 0.84%
$108.69
price up icon 1.31%
$27.07
price up icon 2.65%
$107.34
price down icon 0.15%
biotechnology ONC
$299.01
price down icon 0.70%
Cap:     |  Volume (24h):